Dezamizumab
Term · Oncology and biomedicine · MLC-T-ONC-013019
A fully humanized monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Upon intravenous administration, dezamizumab binds to SAP in amyloid deposits, thereby activating compliment and triggering the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.
| Identifier | MLC-T-ONC-013019 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-SAP mAb; anti-SAP monoclonal antibody |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013019",
"term": "Dezamizumab",
"field": "Oncology and biomedicine",
"definition": "A fully humanized monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Upon intravenous administration, dezamizumab binds to SAP in amyloid deposits, thereby activating compliment and triggering the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.",
"synonyms": [
"anti-SAP mAb",
"anti-SAP monoclonal antibody"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dezamizumab/"
}
Record 5,906 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.